Slingshot members are tracking this event:
Aimmune (AIMT) Expects to Complete Enrollment for Phase 3 PALISADE Trial Evaluating AR101 in Peanut Allergies in H2 2016
Slingshot Insights Explained
Sep 20, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 3 Palisade Trial, Complete Enrollment, H2 2016, Peanut Allergies